Shares of Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) have been given a consensus recommendation of “Hold” by the six brokerages that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company.
SAUHY has been the subject of a number of research reports. Morgan Stanley reaffirmed an “underweight” rating on shares of Straumann in a report on Monday, December 15th. Deutsche Bank Aktiengesellschaft raised shares of Straumann from a “hold” rating to a “buy” rating in a research report on Friday, October 31st. UBS Group upgraded shares of Straumann from a “sell” rating to a “neutral” rating in a research note on Tuesday, November 4th. Finally, Citigroup reiterated a “sell” rating on shares of Straumann in a research note on Wednesday, January 14th.
Get Our Latest Report on Straumann
Straumann Stock Down 1.9%
About Straumann
Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.
In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.
Featured Stories
- Five stocks we like better than Straumann
- This $15 Stock Could Go Down as the #1 Stock of 2026
- I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)
- America’s 1776 happening again
- Trump & Musk’s Secret Bet on Silver — Exposed
- Your Bank Account Is No Longer Safe
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.
